Performance / Research index
Ipamorelin
Ipamorelin is a synthetic five-amino-acid peptide investigated as a growth hormone secretagogue. It has also been studied for activity at the ghrelin receptor and for questions concerning gastrointestinal motility. These are related research contexts, but they do not establish the same outcomes.
Names used in the literature: Ipamorelin · Ipamorelina
Read the evidence and its sources ↓That presentation is not part of this listing. Review the available options before adding a selection.
Ipamorelin 5 mg
- Presentation
- 5 mg
- Catalog reference
- PMX-IPAM-10
Ipamorelin 10 mg
- Presentation
- 10 mg
- Catalog reference
- PMX-IPAM-10MG
Availability and documentation await confirmation. Listed quantities identify catalog presentations, not instructions for use.
What selectivity meant in the original study
The 1998 pharmacology publication investigated GH release and other hormonal responses in experimental models. Selective describes comparisons within those experiments. It does not mean a universal absence of adverse effects, and does not demonstrate benefits for sleep, muscle mass or aging in people who use a catalog product.
Sources: [1]
Hormonal response in volunteers
A study in healthy men measured ipamorelin and GH concentrations to build a pharmacokinetic and pharmacodynamic model. It characterized exposure and hormonal response, rather than measuring muscle gain.
Sources: [4]
The gastrointestinal research question
A rodent study examined gastric emptying after surgery and intestinal manipulation. Its findings supported investigation of mechanisms involving the ghrelin receptor and gastric contractility. This model reproduces aspects of a postoperative disturbance; it is not equivalent to studying everyday digestion, athletic performance or general recovery in human participants.
Sources: [2]
What happened in the clinical trial
A phase 2 trial enrolled 117 bowel-resection patients; 114 entered its safety and modified efficacy populations. It found no significant differences from placebo in the main and secondary efficacy analyses. This illustrates why a preclinical signal is insufficient to establish clinical benefit, even when the mechanism offers a plausible hypothesis.
Sources: [3]
Questions about this reference
Does GH release demonstrate muscle growth?
No. A hormonal response and a clinical change in muscle are different outcomes. The cited pharmacology study does not establish effectiveness for increasing muscle mass or validate that claim for the catalog product.
Is faster postoperative recovery established for ipamorelin?
The cited trial did not demonstrate a significant difference from placebo on its efficacy measures. Its setting was inpatient bowel resection, so it also cannot support general claims about recovery in other settings.
Sources and original reading
- Ipamorelin, the first selective growth hormone secretagogue
- Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
- Prospective, randomized, controlled, proof-of-concept study of ipamorelin for postoperative ileus
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Content updated: . How this content is prepared and checked.
Understand before comparing